Pacira Pharma (PCRX) Announces Estimated $67.2M Q4 EXPAREL Revenues

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced estimated EXPAREL® (bupivacaine liposome injectable suspension) and total revenues for the fourth quarter and full-year 2015. These estimates, which are unaudited, are based on management’s preliminary financial analysis.

“We are pleased with the strong finish to 2015 and the preliminary revenues that benefited from a solid fourth quarter—seasonally the strongest period of the year for procedure volumes,” said Dave Stack, chief executive officer and chairman of Pacira. “We are excited to have achieved a resolution with the FDA at the end of the quarter. In 2016, we will refocus our efforts to bolster the Pacira brand through targeted clinical studies, strategic commercial initiatives, and healthcare provider and patient-focused programs that seek to support the EXPAREL and DepoFoam® pipelines, and additional expansion opportunities.”

Fourth Quarter 2015

• EXPAREL revenues were an estimated $67.2 million, compared to $59.0 million in the fourth quarter of 2014.
• Total revenues were an estimated $69.4 million, compared to $61.8 million in the fourth quarter of 2014.

Full-Year 2015

• EXPAREL revenues were an estimated $239.9 million, compared to $188.5 million in 2014.
• Total revenues were an estimated $249.0 million, compared to $197.7 million in 2014.

Pacira will provide final financial results and additional information on the fourth quarter and year-end 2015 performance in the earnings press release and conference call expected in late February.

You May Also Be Interested In

• Chevron (CVX) earnings fall short while revenue tops estimates in Q1
• Ball Corporation (BALL) Tops Q1 EPS by 12c
• Portland General Electric (POR) Tops Q1 EPS by 6c